37th week of 2008 patent applcation highlights part 38 |
Patent application number | Title | Published |
20080219906 | Multilayered Catalyst Compositions - A multilayered, three-way conversion catalyst having the capability of simultaneously catalyzing the oxidation of hydrocarbons and carbon monoxide and the reduction of nitrogen oxides is disclosed. Provided is a catalytic material of at least four layers in conjunction with a carrier, where each of the layers includes a support, at least three layers comprise a precious metal component, and at least one layer comprises an oxygen storage component (OSC). The catalytic material can further comprise a fifth layer, where at least four layers comprise a precious metal component, at least one layer comprises an oxygen storage component, and at least one layer is substantially free of an oxygen storage component. | 2008-09-11 |
20080219907 | EXHAUST GAS PURIFYING METHOD FOR FUEL CELL VEHICLE AND EXHAUST GAS PURIFYING SYSTEM FOR FUEL CELL VEHICLE - An exhaust gas purifying method for a fuel cell vehicle comprises preparing an exhaust gas purifying system for the fuel cell vehicle, the exhaust gas purifying system including a methane removal catalyst for accelerating the conversion of methane into hydrogen and carbon monoxide. The methane removal catalyst comprises a catalytic ingredient including at least one of rhodium, platinum and palladium. | 2008-09-11 |
20080219908 | Method For Cleaning Exhaust Gases Produced By A Sintering Process For Ores And/Or Other Metal-Containing Materials In Metal Production - The invention relates to a method for cleaning exhaust gases produced by an ore sintering process in metal production consisting in mixing ores, possibly associated with other metal-containing materials, with a solid fuel, in sintering said materials by simulataneously combusting said solid fuel and in carrying out a distillation process. In such a way that NO | 2008-09-11 |
20080219909 | Phosphorous Pentoxide Producing Methods - A phosphorous pentoxide producing method includes forming a kiln bed using feed agglomerates with a calcium-to-silica mole ratio of less than 1.0 and maintaining a bed temperature at or above 1180° C. along at least 50% of the bed length without exceeding 1380° C. along the entire bed length. Less than 10% of the agglomerates' phosphate input to the kiln remains in the kiln residue as phosphate. Another method includes maintaining a bed temperature at or above 1180° C. along a portion of the bed length and establishing a bed surface-to-volume ratio multiplied by a time for bed heat up to 1180° C. of less than 50 minutes-ft | 2008-09-11 |
20080219910 | Single-Crystal GaN Substrate - Manufacture at lower cost of off-axis GaN single-crystal freestanding substrates having a crystal orientation that is displaced from (0001) instead of (0001) exact. With an off-axis (111) GaAs wafer as a starting substrate, GaN is vapor-deposited onto the starting substrate, which grows GaN crystal that is inclined at the same off-axis angle and in the same direction as is the starting substrate. Misoriented freestanding GaN substrates may be manufactured, utilizing a misoriented (111) GaAs baseplate as a starting substrate, by forming onto the starting substrate a mask having a plurality of apertures, depositing through the mask a GaN single-crystal layer, and then removing the starting substrate. The manufacture of GaN crystal having a misorientation of 0.1° to 25° is made possible. | 2008-09-11 |
20080219911 | Process Of Precipitation for Spheric Manganese Carbonate and the Products Produced Thereby - Disclosed herein are a manganese carbonate useful as a material for spinel-type LiMn | 2008-09-11 |
20080219912 | Particulate matter and methods of obtaining same from a kraft waste reclamation - A method for obtaining particulate calcium carbonate having an average particle size less than about 12 microns is provided. The method includes the steps of (1) withdrawing from a pulp mill a mixture containing calcium carbonate; (2) treating the mixture to remove contaminants contained in the mixture to produce a treated mixture containing calcium carbonate and further having a chemical composition and/or purity which substantially inhibits the fusing together of calcium carbonate particulates; (3) recovering from the treated mixture particulate calcium carbonate having an average particle size less than about 12 microns. The calcium carbonate produced has a high surface area to volume ratio and is therefore highly reactive and suitable for numerous applications such as in the treatment of soil, filler paper production, paint production, and contaminant containment in coal stack emission assemblies. | 2008-09-11 |
20080219913 | Methods for Bulk Synthesis of Carbon Nanotubes - Methods for synthesizing single-wall carbon nanotubes by extracting metals from a carbide by halogen treatment at a temperature ranging between 700 to 1700° C. at ambient or low pressure are provided. | 2008-09-11 |
20080219914 | Method of Cladding Diamond Seeds - The invention relates to a method for manufacture of diamond, the method including the steps of providing a first coating of solvent metal or solvent metal alloy on a diamond seed to create a coated diamond seed, situating the coated diamond seed adjacent a catalyst system comprising a solvent metal and/or a source of carbon, and subjecting the coated diamond seed and catalyst system to increased temperature wherein the melting point of the first coating is at least 20 deg C. below that of the catalyst system. The invention further relates to a compact comprising a plurality of diamond seeds wherein at least one seed includes a first coating comprising a solvent metal and/or solvent metal based alloy, the compact further comprising a catalyst system comprising a solvent metal and/or a source of carbon wherein the melting point of the first coating is at least 20 deg C. below that of the catalyst system. | 2008-09-11 |
20080219915 | Carbon black, method of producing carbon black, and device for implementing the method - The invention relates to a carbon black having an aggregate size distribution which has a (d | 2008-09-11 |
20080219916 | Peroxide Decomposition Catalyst - An object of the present invention is to provide a catalyst which decomposes a peroxide effectively and economically under a high temperature while suppressing generation of free radicals, and the present invention provides a peroxide decomposition catalyst containing a base metal atom, wherein a value A indicating a free radical generation amount represented by the (equation 1) is not more than 0.20, and a value B indicating a reaction rate represented by the (equation 2), which can be easily applied to utility such as an agent for preventing deterioration of a polymer electrolyte-type fuel cell and a water electrolysis apparatus, and an antioxidant for medicaments, agrochemicals and foods. | 2008-09-11 |
20080219917 | HARMONIZED WATER AND AQUEOUS SOLUTIONS - A composition of mater comprising a harmonized cluster of water molecules with Fibonacci chains between them and ordered water molecules based on hydrogen bonds that each water molecule interacts with three other water molecules having a magnetic spectra as shown in FIG. | 2008-09-11 |
20080219918 | CATALYST FOR FUEL REFORMING AND METHOD OF PRODUCING HYDROGEN USING THE SAME - A catalyst for fuel reforming including a metal catalyst that includes at least one active component A selected from the group consisting of Pt, Pd, Ir, Rh and Ru; and an active component B that is at least one metal selected from the group consisting of Mo, V, W, Cr, Re, Co, Ce and Fe, oxides thereof, alloys thereof, or mixtures thereof, and a carrier impregnated with the metal catalyst, and a method of producing hydrogen by performing a fuel reforming reaction using the catalyst for fuel reforming. The catalyst for fuel reforming has excellent catalytic activity at a low temperature and improved hydrogen purity. Therefore, when the catalyst for fuel reforming is used, high-purity hydrogen, which can be used as a fuel of a fuel cell, can be produced with high purity. | 2008-09-11 |
20080219919 | Cytotoxicity mediation of cells evidencing surface expression of CD44 - This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 2008-09-11 |
20080219920 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies - The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. | 2008-09-11 |
20080219921 | Novel Technetium and Rhenium Complexes. - Novel radioactive technetium and rhenium complexes comprising tripodal ligands are provided by the present invention. In particular, Tc(I) complexes are provided by the present invention. Novel ligands suitable for the formation of the technetium and rhenium complexes of the invention are also provided, as well as radiopharmaceutical compositions comprising said complexes, kits for their preparation. The invention also relates to the us of | 2008-09-11 |
20080219922 | Alzheimer's Disease Imaging Agents - This invention provides compounds and methods of imaging amyloid deposits using radiolabeled compounds. This invention also provides a method of inhibiting the aggregation of amyloid proteins to form amyloid plaques or deposits, a method of determining a therapeutic compound's ability to inhibit aggregation of amyloid protein, and a method of delivering a therapeutic agent to amyloid deposits. | 2008-09-11 |
20080219923 | Method and Kit for the Production of Particles Labelled with Rhenium-188 - Rhenium-188 labeled particles are produced by suspending particles of an organic polymer or a biopolymer in a solution wherein the solution contains a water-soluble tin-II salt and a Re-188 perrhenate salt with a radioactivity of 1,000 MBq to 60,000 MBq and wherein the solution has initially a pH value of pH 1 to pH 3; heating the solution of step a) to 80° C. to 100° C.; and, after 45 minutes to 70 minutes of heating, increasing and adjusting the pH value to a pH value of pH 5 to pH 8.5. | 2008-09-11 |
20080219924 | Imaging, diagnosis and treatment of disease - The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium. | 2008-09-11 |
20080219926 | SERS MOLECULAR PROBE FOR DIAGNOSTICS AND THERAPY AND METHODS OF USE THEREOF - An oligonucleotide-based SERS molecular probe (SMP) includes a nanoparticle having at least a metal component, and at least one pin loop, the pin loop including a loop sequence complementary to at least one target sequence, a first stem attached to one end of the loop sequence, a second stem attached to the other end of the loop sequence, and at least one SERS active label attached to the first stem. The nanoparticle is attached to the second stem. The probe generates a stronger SERS signal upon irradiation with excitation radiation when not bound to the target sequence as compared to the SERS signal generated following hybridization of the probe with the target sequence. | 2008-09-11 |
20080219927 | ADENOSINE DERIVATIVE FORMULATIONS FOR MEDICAL IMAGING - A stable composition useful for myocardial perfusion imaging contains one or more 2-alkynyladenosine derivatives; and a solvent which is made up of water and hydroxypropyl-β-cyclodextrin. | 2008-09-11 |
20080219928 | Measuring Gastrointestinal Parameters - The present application relates to methods for determining gastric residual volumes and amounts of dietary formula in gastric contents using measurements of soluble solids concentrations in gastric contents, and in some embodiments, a concentrate having a relatively high concentration of soluble solids. The methods can be used for measuring gastric residual volumes of subjects who have fasted or have a low or reduced gastric content. | 2008-09-11 |
20080219929 | Neurofibrillary labels - A method for determining the Braak stage of neurofibrillary degeneration associated with a tauopathy in a subject having neurofibrillary degeneration is disclosed. The method comprises the steps of (i) administering to the subject a conjugated, chelated or detectable chemical group-associated ligand that labels aggregated paired helical filament (PHF) tau protein and is capable of crossing the blood brain barrier; (ii) determining the presence and\or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, and (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. Preferred ligands include sulphonated-benzothiazole-like compounds and diamonophenothiazines. | 2008-09-11 |
20080219930 | Method for the evaluation of dengue virus therapeutic agents - The inventive subject matter relates to a method for evaluating potential compounds and vaccines for the prevention or treatment of dengue virus infection. The method utilizes pigs as an animal model for the evaluation of test vaccine or drug compounds. The breeds that can be utilized and in the inventive method include Yorkshire or Lancashire as well as miniature pig breeds. | 2008-09-11 |
20080219931 | Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies - The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent. | 2008-09-11 |
20080219932 | Magnetic resonance spectroscopy of breast biopsy to determine pathology, vascularization and nodal involvement - Robust classification methods analyse magnetic resonance spectroscopy (MRS) data (spectra) of fine needle aspirates taken from breast tumours. The resultant data when compared with the histopathology and clinical criteria provide computerized classification-based diagnosis and prognosis with a very high degree of accuracy and reliability. Diagnostic correlation performed between the spectra and standard synoptic pathology findings contain detail regarding the pathology (malignant versus benign), vascular invasion by the primary cancer and lymph node involvement of the excised axillary lymph nodes. The classification strategy consisted of three stages: pre-processing of MR magnitude spectra to identify optimal spectral regions, cross-validated Linear Discriminant Analysis, and classification aggregation via Computerised Consensus Diagnosis. Malignant tissue was distinguished from benign lesions with an overall accuracy of 93%. From the same spectrum, lymph node involvement was predicted with an accuracy of 95% and tumour vascularisation with an overall accuracy of 92%. | 2008-09-11 |
20080219933 | Fluorescence-Mediated Molecular Tomography - This invention relates to a fluorescence-mediated molecular tomographic imaging system, designed to detect near-infrared fluorescence activation in deep tissues. The system can use targeted fluorescent molecular probes or highly sensitive activatable fluorescence molecular probes. Such probes add molecular specificity and yield high fluorescence contrast, to allow early detection and molecular target assessment of diseased tissue, such as cancers, in vivo. The new tomographic imaging system enables three-dimensional localization in deep tissues and quantitation of molecular probes. | 2008-09-11 |
20080219934 | Anionic, Ampholytic Copolymers for Low-Voc-Compositions - The present invention provides cosmetic compositions containing a copolymer obtainable by the copolymerization of at least one methacrylic acid ester, methacrylic acid, acrylic acid, optionally at least one compound containing amino groups and polymerizable by free radical polymerization, and optionally other olefinically unsaturated compounds polymerizable by free radical polymerization. The copolymerization can be carried out in the presence of silicones f) containing polyalkylene oxide. | 2008-09-11 |
20080219935 | Phase Transitive Breath Care Products - Disclosed herein is a breath freshener whose phase is changed depending on the condition of use. A breath freshener of W/O emulsion phase comprises a monoglyceride as a main base, a polymer, an effective component for breath freshening, and a solvent. A breath freshener of solution phase comprises a monoglyceride as a main base, a polyol, a polymer, an effective component for breath freshening, and a solvent. Since the breath fresheners are sufficiently flowable to spray when being sprayed into the oral cavity, they are easy to use. In addition, the breath fresheners are phase-changed into a cubic phase by moisture, e.g., saliva, after being sprayed into the oral cavity, resulting in an increase in the viscosity and adhesiveness of the breath fresheners. Therefore, the effective breath freshening ingredient is slowly released from the breath fresheners, and as a result, continuous breath freshening effects are achieved. | 2008-09-11 |
20080219936 | Skin depigmenting compositions comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent - Depigmenting compositions for the skin, comprise, formulated into a physiologically acceptable medium, adapalene, at least one depigmenting agent and at least one anti-inflammatory agent, and to the pharmaceutical/cosmetic applications thereof. | 2008-09-11 |
20080219937 | Use of at Least One 2-Alkyl Furan, as Depigmenting or Lightening Active Principle - The invention concerns the cosmetic use of at least one 2-alkyl furan, as depigmenting active principle, in a depigmenting composition, as well as the associated cosmetic treatment method. The invention also concerns the use of at least one 2-alkyl furan for preparing an active drug as depigmenting agent. The invention further concerns a depigmenting cosmetic composition comprising as depigmenting active principle at least one 2-alkyl furan. | 2008-09-11 |
20080219938 | SPF compositions - A composition comprising; water purified using ozonation, ionization, or distillation or any combination thereof wherein alcohol may be substituted for, or combined with water; at least one emollient including but not limited to chitosan, and | 2008-09-11 |
20080219939 | Sunblock formulations - Disclosed is a sunblock composition providing ultraviolet radiation protective agents that can be used in various compositions or formulations, specifically those of a higher SPF value that utilize micronized zinc dioxide, micronized titanium oxide, glass microspheres, glycerin and/or aloe, a carrier oil, and an emulsifier. The emulsifier is selected from the group comprising fatty acid salts, fatty acid sucrose esters, phospholipids, borate salts, cocoate esters, essential oils, non-petroleum derived waxes, chitosan, water and/or ethanol, a thickening agent, a pigment and a carotenoid or any single or multiple combination of this group of emulsifiers. | 2008-09-11 |
20080219940 | Colored cosmetic composition having soft focus effect - Colored cosmetic compositions include, in a physiologically acceptable medium, a filler and a coloring agent, the coloring agent having a transparency and/or being present in a quantity such that presence of the coloring agent with the filler in the composition confers a saturation C* of greater than or equal to 17, a hemispherical transmittance greater of than or equal to 70% and a soft focus index H of greater than or equal to 40%. | 2008-09-11 |
20080219941 | COMPOSITIONS AND METHODS FOR REMOVING HAIR STYLING AIDS - Disclosed are compositions for solubilizing and/or removing a hair styling aid composition from hair. The compositions comprise at least one active solvent, wherein the active solvent is a glycol or an ester; and a carrier composition comprising a liquid vehicle. Also disclosed are methods for solubilizing and/or removing hair styling aids from hair. | 2008-09-11 |
20080219942 | Hair treatment composition - An improved hair treatment composition that strengthens cellulosic fiber found in the composition of hair, that eliminates the degradation of hair, and that provides for skin protection from the adverse reaction of caustic alkaline preparations found in professional hair products that are used in the bleaching and strengthening hair. The composition of the present invention may also be safely used by non professional hair stylist without deteriorating the texture and quality of the end user's hair, without permanent or temporary hair loss, and without injury to the scalp. | 2008-09-11 |
20080219943 | Composition for Coating Keratin Fibres Comprising a Block Polymer and a Semicrystalline Polymer - A subject of the invention is a composition for coating keratin fibres comprising a cosmetically acceptable medium, a block polymer, and at least one semicrystalline polymer. A subject of the invention is also the use of such a composition for obtaining a makeup for the keratin fibres, in particular the eyelashes, which is charging and/or homogeneous and/or smooth and/or has good staying power. | 2008-09-11 |
20080219944 | Polymer based antifouling coating - A coating composition comprising (i) at least one resin powder and (ii) at least one component selected from the group consisting of a metal compound, biocide and fluoropolymers. In particular, one antifouling composition that can be used on underwater stationary structures that sit in highly fouling environments comprises polyethylene as a resin powder, and copper in the form of cuprous or cupric oxide. | 2008-09-11 |
20080219945 | PHEROMONES AND METHOD OF PREVENTING INFESTATION OF CONTARINIA NASTURTII - The present invention relates to pheromone mixture comprising 2,9 diacetoxyundecane, 2,10-diacetoxyundecane and 2-acetoxyundecane, as a racemate or, biologically active stereoisomers thereof, as well as a method for monitoring and/or mating disruption of swede midge, | 2008-09-11 |
20080219946 | THERAPEUTIC AGENT AND METHOD FOR OVULATION DISORDER CAUSED BY LUTEINIZED UNRUPTURED FOLLICLE - A therapeutic agent for ovulation disorder of the present invention is characterized in comprising Granulocyte colony-stimulating factor; and that the ovulation disorder is caused by Luteinized Unruptured Follicle. | 2008-09-11 |
20080219947 | Single chain trimers and uses therefor - Single chain trimer (SCT) molecules are disclosed, comprising an MHC antigen peptide sequence, a β | 2008-09-11 |
20080219948 | Methods for treatment of behcet's disease using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2008-09-11 |
20080219949 | Methods for treating brain cancer using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2008-09-11 |
20080219950 | DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS - The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. | 2008-09-11 |
20080219951 | Stabilization of Biologically Active Proteins With Mixtures of Polysaccharides and Amino Acid Based Compounds - The invention provides heat stable aqueous solutions or gels comprising a biologically active protein and a stabilizing effective amount of a mixture of a polysaccharide and an amino acid based compound. The invention also discloses stabilized solutions or gels suitable for use in an implantable drug delivery device at body temperature, and a device containing the stabilized solution or gels. | 2008-09-11 |
20080219952 | Process For the Preparation of Glycosylated Interferon Beta - The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern. | 2008-09-11 |
20080219953 | Cosmid dna constructs and methods of making and using same - Methods of inducing immune responses in individuals against a pathogen are disclosed. Methods of treating individuals susceptible to or suffering from a disease associated with a genetic defect which results in the non-production or under production of a protein or the production of a non-functioning or partially functioning protein are disclosed. Methods of delivering a protein to an individual are disclosed. Pharmaceutical compositions that comprise cosmids are disclosed. | 2008-09-11 |
20080219954 | Method for rapid screening of bacterial transformants and novel simian adenovirus proteins - Chimpanzee serotype C68 proteins, peptides, and polypeptide are provided. Also provided are novel adenoviruses derived from these proteins, as well as compositions containing these proteins and methods of using same for immunization and therapy. Further, a rapid method for screening recombinant transformants using a visually detectable method is described. | 2008-09-11 |
20080219955 | Method of Producing Purified Neural Stem Cells and Related Methods of Treating a Patient - The present invention provides a method of producing purified neural stem cells, comprising harvesting fluid containing neural stem cells from cerebrospinal fluid surrounding the spinal cord of an individual, isolating the neural stem cells from the fluid, culturing the neural stem cells in a culture medium effective to induce proliferation of the neural stem cells and purifying the cultured neural stem cells. Also provided is a method of treating a patient afflicted with a neurological condition, in which the purified neural stem cells are administered autologously into the same individual or heterologously to a patient other than the individual. Administration of the purified neural stem cells results in the purified neural stem cells propagating in the site of the brain region afflicted with the neurological condition. | 2008-09-11 |
20080219956 | HLA HOMOZYGOUS CELLS AND METHODS OF USE THEREOF - The present invention provides methods of generating a mammalian cell that is homozygous at a locus of interest, as well as cells made by the method. The present invention further provides methods of using the cells. | 2008-09-11 |
20080219957 | Method of Deriving Mesenchymal Stem Cells - We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line. | 2008-09-11 |
20080219958 | METHOD FOR INDUCING AN ANTI-TUMOR AND ANTI-CACHEXIA IMMUNE RESPONSE IN MAMMALS - The invention relates to inducing an immune response toward tumor associated antigens and in particular to the administration of high molecular weight isolates of autologous urine either alone, with adjuvants, or with antigen presenting cells. The antigen presenting cells have been cocultured with isolates of autologous urine. The invention can also be used to treat cachexia in cancer or AIDS patients. | 2008-09-11 |
20080219959 | Support Having Nanostructured Titanium Dioxide Film And Uses Thereof - The present invention relates to supports for bioassays and the use thereof in cell culturing and in cell-based methods and assays. More precisely, the invention provides solid materials coated with films of nanostructured titanium dioxide suitable for the immobilisation of viruses and for cell-adhesion. The nanostructured TiO2 film-coated support of the invention is particularly useful for the preparation of microarrays for genetic and phenotypic analysis. | 2008-09-11 |
20080219960 | Novel Efficient Production Process for Capsular Polysaccharides of Pathogenic Grampositive Bacteria by Heterologous Expression and Secretion of Complex Polysaccharides in Non-Pathogenic, Non-Invasive Gram-Positive Bacteria - The current invention provides methods and means for heterologous expression, production and/or secretion of complex capsular polysaccharides in non-pathogenic, non-invasive Gram-positive bacteria. The invention in particular provides non-pathogenic, non-invasive Gram-positive bacteria capable of expression and/or secretion of heterologous, complex polysaccharides from a pathogenic bacterial species. Such bacteria and polysaccharides produced therein may be applied according to the invention to provide compositions for vaccination for the treatment and prevention of infectious bacterial diseases. | 2008-09-11 |
20080219961 | Method for Stabilising Pharmaceutical Administration Forms Comprising Microorganisms - The invention relates to a method for stabilising solid pharmaceutical administration forms which comprises at least one species of microorganism, and to a pack comprising packaging and a solid pharmaceutical administration form which comprises at least one species of microorganism. | 2008-09-11 |
20080219962 | Method to Enhance the Bone Formation Activity of Bmp by Runx2 Acetylation - The present invention relates to a method to enhance the activity of Runx2, a major target protein of Bone Mophogenetic Protein (BMP), by Runx2 acetylation, more precisely, a method to activate BMP-mediated bone formation pathway by protecting Runx2 from ubiquitination, indicating that Runx2 is protected from degradation by the increase of Runx2 acetylation making the protein more stable. The method to enhance Runx2 activity of the present invention can be utilized for the prevention and the treatment of bone disease such as osteoporosis, osteogenesis imperfecta, periodontal disease and fracture, by inducing bone formation by inhibiting Runx2 degradation. | 2008-09-11 |
20080219963 | Composition Containing Micronutrients With Improved Anti-Oxidant Activity And The Use Thereof - Compositions in fine powder form that can be obtained by means of a dry co-grinding process of an at least ternary mixture consisting of an active substance, a carrier and at least one auxiliary co-grinding substance, wherein the active substance is constituted by one or more micronutrient substances with particular antioxidant activity. Such compositions have shown a significant increase in active substance antioxidant power in comparison to solutions of equal active substance content. Said effect is particularly useful for uses for active substances included in antioxidant compositions in the pharmaceutical, cosmetic and dietary-nutritional fields. | 2008-09-11 |
20080219964 | Methods and products for enhancing energy and nutrition in human beings - Methods for increasing energy in men and women include ingesting internally, twice a day, products that include, for women, multivitamins, multiminerals, high-calcium bone support products, high-ORAC super food products, and enzymes, and, for men, multivitamins, multiminerals, prostate support products, high-ORAC super food products, and enzymes. | 2008-09-11 |
20080219965 | Phytase Variants - The present invention relates to phytase variants, their preparation and uses, which phytase variants, when aligned according to FIG. | 2008-09-11 |
20080219966 | METHODS OF TREATING PERVASIVE DEVELOPMENT DISORDERS - A therapeutic method for treating an individual diagnosed with PDD pervasive developmental disorder comprises determining the efficacy of digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. A method for reducing the amount of methylphenidate (Ritalin) being taken by an individual with attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) by administering a therapeutic amount of digestive enzymes is also provided. | 2008-09-11 |
20080219967 | Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases - Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses. | 2008-09-11 |
20080219968 | Sos1 inhibitors - Inhibitors of human Sos1, including antisense oligonucleotides, methods, and compositions specific for human Sos1, are provided. Methods of using the compositions for modulating Sos1 expression and for regulating cell growth, particularly tumor cell growth, are also provided. | 2008-09-11 |
20080219969 | Concentrate of Chikungunya-Specific Immunoglobulins as a Medicinal Product - The invention concerns a new medicinal product for the treatment of chikungunya, i.e a concentrate of chikungunya-specific immunoglobulins, as well as its process of preparation. | 2008-09-11 |
20080219970 | IDENTIFICATION AND MOLECULAR CHARACTERISATION OF PROTEINS, EXPRESSED IN THE IXODES RICINUS SALIVARY GLANDS - The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the | 2008-09-11 |
20080219971 | HUMAN ANTI-CD100 ANTIBODIES - Compositions and methods are provided for treating diseases associated with CD100, including certain types of cancers, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejections, and invasive angiogenesis. Compositions include anti-CD100 antibodies capable of binding to a soluble human CD100 antigen or a CD100 antigen located on the surface of a human CD100-expressing cell, wherein the antibody has CD100 blocking activity that is achieved by having at least one optimized CDR or FWR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD100 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD100 antibodies. | 2008-09-11 |
20080219972 | Prostatic Acid Phosphatase (Pap) Materials and Methods of Use Thereof in the Prophylactic and Therapeutic Treatment of Prostate Cancer - A nucleic acid molecule comprising at least one nucleotide sequence encoding SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a polypeptide consisting of SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a composition comprising APC, which have been exposed to the polypeptide, and a method of administering same to treat prostate cancer; a composition comprising T-cells, which are specific for an epitope in a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; a composition comprising an anti-idiotypic antibody having an internal image of an epitope of a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; and an immortal B-cell line that produces an anti-idiotypic monoclonal antibody having an internal image of an epitope of a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41. | 2008-09-11 |
20080219973 | Pharmaceutical Composition Having Inhibitory Effect on Overproduction and Accumulation of Extracellular Matrix - A pharmaceutical composition having an inhibitory effect on the overproduction and the accumulation of extracellular matrix, said composition comprising as an active ingredient a compound that inhibits the biological activity of galectin-3, which pharmaceutical composition can serve as a therapeutic or preventive agent for glomerular nephritis, diabetic nephropathy or tissue fibrosis, as well as the use of said compound for the production of pharmaceuticals for the above-mentioned use, and a method for inhibition of the overproduction and accumulation of the extracellular matrix. | 2008-09-11 |
20080219974 | OPTIMIZED ANTIBODIES THAT TARGET HM1.24 - The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed. | 2008-09-11 |
20080219975 | VEGFR3 INHIBITORS - The present invention relates to the use of some of the macrocyclic quinazoline derivatives described in PCT publication WO2004/105765 as inhibitors of VEGFR3 mediated biological activities, especially those activities which are mediated by VEGFR3 ligands VEGF-C and/or VEGF-D. | 2008-09-11 |
20080219976 | METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF STAPHYLOCOCCAL INFECTIONS - The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, | 2008-09-11 |
20080219977 | Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer - The invention relates to a method of treating a warm-blooded animal having pancreatic cancer, in particular it relates
| 2008-09-11 |
20080219978 | Soluble FcgammaRIA and related methods - Disclosed are soluble FcγRIA polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble FcγRIA polypeptides. | 2008-09-11 |
20080219979 | Methods of using IL-17 receptor A antibodies - The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation. | 2008-09-11 |
20080219980 | Bi-Specific Complexes for Targeting Cells Involved in Allergic-Type Reactions, Compositions and Uses Thereof - Disclosed are bi-specific complexes aimed at inhibiting mast cells, eosinophils and/or basophils, and thus, at inhibiting allergy-type reactions. In particular, said complexes are best exemplified by bi-specific antibodies, which bind to two targets present in the same cell. One target is the inhibitory receptor IRp60. The second target is a cell-specific activator, e.g. IgE, cKIT, FcεRI, IL5R or CCR3. Binding of the bi-specific antibody to its targets results in the induction of an inhibitory pathway, through the inhibition of the signaling from the activator. Compositions and uses of the bi-specific complexes are also described. | 2008-09-11 |
20080219981 | Diagnostic Kit for Solid Cancer and Medicament for Solid Cancer Therapy - The present invention provides novel solid cancer antigenic proteins, and diagnostic kits for solid cancer and therapeutic agents for solid cancer based on the antigenic proteins. Specifically, the present invention provides a human solid cancer antigenic polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75. | 2008-09-11 |
20080219982 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2008-09-11 |
20080219983 | Antagonists of Factor VIII Interaction with Low-Density Lipoprotein Receptor Related Protein - The present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A. The present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor VIII half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A. | 2008-09-11 |
20080219984 | Nogo receptor-mediated blockade of axonal growth - Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease. | 2008-09-11 |
20080219985 | PROK2 ANTAGONISTS AND METHODS OF USE - The present invention provides methods of using PROK2 and PROK1 antagonist, including monoclonal antibodies to treat inflammation, angiogenesis, and cancer. | 2008-09-11 |
20080219986 | Polynucleotides and polypeptides BASB033 from neisseria meningitidis and their uses - The invention provides BASB033 polypeptides and polynucleotides encoding BASB033 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 2008-09-11 |
20080219987 | Novel Phosphorylated Phosphatase Cdc25b Sequences, Antibodies Directed Against Said Sequences and Uses Thereof - A peptide sequence includes a fragment of at least 10 amino acids derived from the following SEQ ID NO:1: DRKMEVEELS | 2008-09-11 |
20080219988 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer. | 2008-09-11 |
20080219989 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2008-09-11 |
20080219990 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2008-09-11 |
20080219991 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2008-09-11 |
20080219992 | Pancreatic cancer secreted targets and uses thereof - The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAST) and antibodies binds to PCAST. The present invention provides that PCAST is used as targets for screening agents that modulates the PCAST activities. Further the present invention provides methods for treating diseases associated with pancreas. | 2008-09-11 |
20080219993 | HUMAN RGR ONCOGENE AND TRUNCATED TRANSCRIPTS THEREOF DETECTED IN T CELL MALIGNANCIES, ANTIBODIES TO THE ENCODED POLYPEPTIDES AND METHODS OF USE - Naturally-occurring variants of human Rgr oncogene protein, in particular, abnormally truncated variants found in T cell malignancies, as well as the human Rgr protein are encompassed by the present invention. Also included are antibodies thereto and nucleic acid molecules encoding human Rgr protein and naturally-occurring variants thereof. The present invention further provides methods for diagnosing and treating T cell malignancies associated with abnormally truncated transcripts of human rgr oncogene and/or abnormal truncation of human Rgr protein. | 2008-09-11 |
20080219994 | MODIFIED BOUGANIN PROTEINS, CYTOTOXINS AND METHODS AND USES THEREOF - The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. | 2008-09-11 |
20080219995 | IL-32 MONOCLONAL ANTIBODIES AND USES THEREOF - The present invention provides monoclonal antibodies specific for interleukin-32 (IL-32, previously referred to as “natural killer cell transcript 4” or “NK4”) and hybridomas secreting monoclonal antibodies specific for IL-32. Also provided are diagnostic methods and kits (e.g., ELISA, Western blot, etc.) which utilize monoclonal antibodies specific for IL-32. | 2008-09-11 |
20080219996 | Molecular Markers Associated with Bone Metastasis - This invention relates generally to the modulation of expression levels of bone sialoprotein (BSP) in tumors, especially a non-small cell lung cancer tumor, as an indicator of progression to bone metastasis. | 2008-09-11 |
20080219997 | Her-2 binding antagonists - There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1 or SEQ ID NO:12, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 10 | 2008-09-11 |
20080219998 | Anti-Thrombotic Agents - The present invention embodies: methods; compounds, their pharmaceutically acceptable analogs, isomer, salts, hydrates, solvates and prodrug derivatives, and pharmaceutically acceptable compositions thereof that have particular biological properties; devices; diagnostic and other assays; and the uses of such methods, compounds, devices and assays. Common throughout these embodiments is specific selective reduction of intravascular thromboplastin antecedent activity, which results in a safe antithrombotic effect. A particularly prominent application or the invention relates to diagnosis and treatment of patients which have, or are at risk of, developing thrombosis, thrombotic injury, or vaso-occlusive diseases, such as myocardial infarction, stroke, restenosis after angioplasty, thrombotic diseases, etc. Another particularly prominent feature of the present invention is its high level of hemostatic safety at optimal efficacy. Also, the present invention is compatible for use in combination with other traditional therapeutic agent such as another antithrombotic, antiplatelet, thrombolytic, or anticoagulant agents. | 2008-09-11 |
20080219999 | Immunoadhesin for the prevention of rhinovirus infection - The immunoadhesions of the present invention are useful in treating rhinovirus infections. The immunoadhesions contain a chimeric ICAM molecule and may optionally also contain J chain and secretory compounds. The chimeric ICAM molecule is a fusion protein that has a rhinovirus receptor protein linked to an immunoglobulin protein. This invention also includes the greatly increased and improved method of producing immunoadhesions in plants. Each of the components of an immunoadhesin is produced in a plant cell and thereby assembles within the plant cell. This method of producing the immunoadhesions of the present invention results in the efficient and economic production of these molecules. The present invention also contemplates the production of immunoadhesions in a variety of eukaryotic cells including plants and mammalian cells. The immunoadhesions of the present invention are useful as a therapeutic against the common cold in humans which is caused by rhinoviruses. | 2008-09-11 |
20080220000 | Methods for Generating Improved Immune Reponse - This application relates to a method for generating an improved immune response in a host. The method involves the step of administering a vectored vaccine in the presence of an agent that impairs Treg cell function. | 2008-09-11 |
20080220001 | CA IX-Specific Inhibitors - Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic sulfonamides, which inhibit the enzymatic activity of MN/CA IX and that are useful for treating patients with preneoplastic/neoplastic disease. Further, the CA IX-specific inhibitors when labeled or linked to an appropriate visualizing means can also be used diagnostically/prognostically for preneoplastic/neoplastic disease, and for imaging use, for example, to detect hypoxic precancerous cells, tumors and/or metastases, by selectively binding to activated CA IX, preferably CA IX activated under hypoxic conditions, and not to inactive CA IX. Such detection of hypoxic conditions can be helpful in determining effective treatment options, and in predicting treatment outcome and the prognosis of disease development. Still further, the CA IX-specific inhibitors can be used therapeutically to selectively target hypoxic cells expressing activated CA IX. The CA IX-specific inhibitors can be labelled or conjugated to radioisotopes for radiotherapy of hypoxic cells. Alternatively, the CA IX-specific inhibitors can be used for gene therapy coupled to vectors for targeted delivery to hypoxic preneoplastic/neoplastic cells expressing activated CA IX on their surfaces. | 2008-09-11 |
20080220002 | MODIFIED TRANSFERIN-ANTIBODY FUSION PROTEINS - Modified fission proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor. | 2008-09-11 |
20080220003 | C5a Receptor Antagonists - The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are individually and independently selected from the group comprising H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, alkoxyl, substituted alkoxyl, aryloxy, substituted aryloxy, arylalkyloxy, substituted arylalkyloxy, acyloxy, substituted acyloxy, halogen, hydroxyl, nitro, cyano, acyl, substituted acyl, mercapto, alkylthio, substituted alkylthio, amino, substituted amino, alkylamino, substituted alkylamino, bisalkyl amino, substituted bisalkyl amino, cyclic amino, substituted cyclic amino, carbamoyl (—CONH | 2008-09-11 |
20080220004 | Use of VEGF inhibitors for treatment of eye disorders - Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy. | 2008-09-11 |
20080220005 | Comb Polymers - The present invention provides a process for producing a comb polymer comprising the steps of: a) providing: (i) (w+z) molar equivalents of a monomer; (ii) one molar equivalent of an initiator compound of formula (IX), wherein B | 2008-09-11 |
20080220006 | Method for Modulating Inflammatory Responses - The present invention is a method for inhibiting T | 2008-09-11 |